

# Medical Oncology Coverage

## Breast

- DCIS
- Invasive



## Skin

- Melanoma
  - Brain Metastasis
  - Ocular



## Hematologic

- CML
- MDS
- Multiple Myeloma



## Gastrointestinal

- Anal
- Colon
- Rectal
- Gastric
- Esophageal
- GE Junction
- Pancreatic



## Genitourinary

- Bladder
- Prostate
  - Adenocarcinoma
  - Small Cell
- Renal Cell
- Testicular
  - Seminoma
  - Non-seminoma
  - Sex cord stromal tumors



## Thoracic

- Mesothelioma
- NSCLC
- SCLC



## Head & Neck

- Hypopharynx
- Larynx
- Nasopharyngeal
- Occult Primary
- Oral Cavity
- Oropharynx
- Other Sites



## Gynecologic

- Ovarian
- Uterine
  - Endometrioid Histology
  - Carcinosarcomas
  - Papillary Serous & Clear Cell Histology
  - Low Grade Endometrial Stromal Sarcoma
  - High Grade Undifferentiated/Leiomyosarcoma



# Medical Oncology: On Pathway Rates

*Data for all customers  
(excluding Private Label centers)  
Medical Oncology  
12 months ended 11/30/16*

Disease	On-Pathway Rate
<a href="#">Bladder</a>	76.0%
<a href="#">Breast</a>	87.0%
<a href="#">CML</a>	76.3%
<a href="#">Colorectal</a>	83.1%
<a href="#">Gastroesophageal</a>	73.1%
<a href="#">Head and Neck</a>	83.2%
<a href="#">Lymphoma and CLL</a>	77.6%
<a href="#">MDS</a>	85.8%
<a href="#">Melanoma</a>	86.3%
<a href="#">Mesothelioma</a>	59.2%
<a href="#">Multiple Myeloma</a>	78.4%
<a href="#">Non-Small Cell Lung</a>	79.1%
<a href="#">Ovarian</a>	68.4%
<a href="#">Pancreatic</a>	85.3%
<a href="#">Prostate</a>	86.4%
<a href="#">Renal Cell</a>	81.8%
<a href="#">Small Cell Lung</a>	81.4%
<a href="#">Testicular</a>	92.0%
<a href="#">Thyroid</a>	82.4%
<a href="#">Uterine</a>	76.9%
<b>MedOnc Total</b>	<b>82.2%</b>